Author

E. Van Allen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:statistical model· 4 Assay:whole-genome sequencing· 3 Assay:bulk RNA-seq· 2 Research Focus:clustering· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

J. Crowdis· 4 shared M. Brown· 3 shared A. K. Tewari· 2 shared J. Park· 2 shared J.-H. Seo· 2 shared M. L. Freedman· 2 shared M. X. He· 2 shared S. H. AlDubayan· 2 shared

Activity by Year

2016-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. Crowdis

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Somatic structural variants driving distinct modes of oncogenesis in melanoma

J. M. Conway, R. Gillani, J. Crowdis, B. Reardon, J. Park, S. Han, B. Titchen, M. Benamar, R. Haq, E. Van Allen

This study analyzes structural variants in melanoma subtypes, identifying distinct genomic properties and molecular drivers that may inform therapeutic strategies.

bioRxiv · Nov 1, 2023 · PreprintCancer Biology

Analysis of evolutionary dynamics and clonal architecture in prostate cancer

J. Conway, A. K. Tewari, S. Y. Camp, S. Han, J. Crowdis, M. X. He, Y. A. Nyame, S. H. AlDubayan, N. Schultz, Z. Szallasi, M. M. Pomerantz, M. L. Freedman, L. Fong, P. S. Nelson, M. Brown, , E. Van Allen

This study analyzes prostate cancer clonal architecture and evolutionary dynamics in 845 tumors, finding that Black patients have more monoclonal tumors but higher recurrence rates, and identifies new mutational signatures linked to subclones.

bioRxiv · Mar 23, 2023 · PreprintCancer Biology

CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapies

J. H. Hwang, R. Arafeh, J.-H. Seo, S. C. Baca, M. Ludwig, T. E. Arnoff, C. Richter, H. E. Bergom, S. McSweeney, J. P. Rennhack, S. A. Klingenberg, A. T. Cheung, J. Kwon, J. So, S. Kregel, , W. Hahn

This study identifies CREB5 as a key driver of resistance to androgen receptor targeting therapies by reprogramming nuclear interactions and activating TGFβ and Wnt signaling pathways.

bioRxiv · Aug 18, 2021Cancer Biology

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer

A. K. Tewari, A. T. M. Cheung, J. Crowdis, J. R. Conway, S. Y. Camp, S. A. Wankowicz, D. G. Livitz, J. Park, R. T. Lis, A. Boosma-Moody, M. X. He, S. H. AlDubayan, Z. Zhang, R. R. McKay, I. Leshchiner, , E. Van Allen

bioRxiv · Apr 20, 2021Cancer Biology

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer

P. Cejas, Y. Xie, A. Font-Tello, K. Lim, S. Symala, X. Qiu, A. Tewari, N. Shah, H. Nguyen, R. Patel, L. Brown, I. Coleman, W. M. Hackeng, L. Brosens, K. Dreijerink, , H. W. Long

This study identifies two distinct subtypes of neuroendocrine prostate cancer based on neuronal transcription factors and highlights their epigenetic convergence and therapeutic implications.

bioRxiv · Sep 13, 2020Cancer Biology

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

T. Nathanson, A. Ahuja, A. Rubinsteyn, B. A. Aksoy, M. D. Hellmann, D. Miao, E. Van Allen, T. Merghoub, J. Wolchok, A. Snyder, J. Hammerbacher

The paper reanalyzes exome and RNA-Seq data from melanoma patients treated with CTLA-4 blockade to assess the predictive value of somatic mutation burden and neoepitope homology to pathogens.

bioRxiv · Nov 17, 2016Cancer Biology